Hepion Pharmaceuticals Ownership 2024 | Who Owns Hepion Pharmaceuticals Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

183.50%

Insider Ownership

0.31%

Retail Ownership

-83.81%

Institutional Holders

27.00

Hepion Pharmaceuticals Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
WELLS FARGO & COMPANY/MN----528-100.00%-Jun 30, 2023
NORTHERN TRUST CORP----132,059-100.00%-Jun 30, 2023
STATE STREET CORP----313,500-100.00%-Jun 30, 2023
VANGUARD GROUP INC----3,310,180-100.00%-Jun 30, 2023
PNC FINANCIAL SERVICES GROUP, INC.----57,534-100.00%-Jun 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----31,535-100.00%-Jun 30, 2023
MORGAN STANLEY----88,216-100.00%-Jun 30, 2023
GROUP ONE TRADING, L.P.----13,128-100.00%-Jun 30, 2023
RENAISSANCE TECHNOLOGIES LLC----284,300-100.00%-Jun 30, 2023
AMUSSEN HUNSAKER ASSOCIATES LLC----13,306-100.00%-Jun 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----656,453-100.00%-Jun 30, 2023
BLACKROCK INC.----1,602,772-100.00%-Jun 30, 2023
BANK OF NEW YORK MELLON CORP----88,715-100.00%-Jun 30, 2023
ENVESTNET ASSET MANAGEMENT INC----156,909-100.00%-Jun 30, 2023
CITADEL ADVISORS LLC----1,648-100.00%-Jun 30, 2023
SIGNATUREFD, LLC----2-100.00%-Jun 30, 2023
HARBOR INVESTMENT ADVISORY, LLC----1-100.00%-Jun 30, 2023
TWO SIGMA ADVISERS, LP----25,900-100.00%-Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----10,564-100.00%-Jun 30, 2023
VIRTU FINANCIAL LLC----53,501-100.00%-Jun 30, 2023

Hepion Pharmaceuticals's largest institutional shareholder is WELLS FARGO & COMPANY/MN, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
WELLS FARGO & COMPANY/MN----528-100.00%-Jun 30, 2023
NORTHERN TRUST CORP----132,059-100.00%-Jun 30, 2023
STATE STREET CORP----313,500-100.00%-Jun 30, 2023
VANGUARD GROUP INC----3,310,180-100.00%-Jun 30, 2023
PNC FINANCIAL SERVICES GROUP, INC.----57,534-100.00%-Jun 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----31,535-100.00%-Jun 30, 2023
MORGAN STANLEY----88,216-100.00%-Jun 30, 2023
GROUP ONE TRADING, L.P.----13,128-100.00%-Jun 30, 2023
RENAISSANCE TECHNOLOGIES LLC----284,300-100.00%-Jun 30, 2023
AMUSSEN HUNSAKER ASSOCIATES LLC----13,306-100.00%-Jun 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----656,453-100.00%-Jun 30, 2023
BLACKROCK INC.----1,602,772-100.00%-Jun 30, 2023
BANK OF NEW YORK MELLON CORP----88,715-100.00%-Jun 30, 2023
ENVESTNET ASSET MANAGEMENT INC----156,909-100.00%-Jun 30, 2023
CITADEL ADVISORS LLC----1,648-100.00%-Jun 30, 2023
SIGNATUREFD, LLC----2-100.00%-Jun 30, 2023
HARBOR INVESTMENT ADVISORY, LLC----1-100.00%-Jun 30, 2023
TWO SIGMA ADVISERS, LP----25,900-100.00%-Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----10,564-100.00%-Jun 30, 2023
VIRTU FINANCIAL LLC----53,501-100.00%-Jun 30, 2023

The largest Hepion Pharmaceuticals shareholder by % of total assets is WELLS FARGO & COMPANY/MN. The company owns 0.00 shares of Hepion Pharmaceuticals (HEPA), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ALLWORTH FINANCIAL LP----1-100.00%-Jun 30, 2023
HARBOR INVESTMENT ADVISORY, LLC----1-100.00%-Jun 30, 2023
SIGNATUREFD, LLC----2-100.00%-Jun 30, 2023
WELLS FARGO & COMPANY/MN----528-100.00%-Jun 30, 2023
CITADEL ADVISORS LLC----1,648-100.00%-Jun 30, 2023
AMPLIUS WEALTH ADVISORS, LLC----10,000-100.00%-Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----10,564-100.00%-Jun 30, 2023
GROUP ONE TRADING, L.P.----13,128-100.00%-Jun 30, 2023
AMUSSEN HUNSAKER ASSOCIATES LLC----13,306-100.00%-Jun 30, 2023
UBS GROUP AG----14,070-100.00%-Jun 30, 2023
CETERA INVESTMENT ADVISERS----19,746-100.00%-Jun 30, 2023
TWO SIGMA ADVISERS, LP----25,900-100.00%-Jun 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----31,535-100.00%-Jun 30, 2023
ADVISOR GROUP HOLDINGS, INC.----47,524-100.00%-Jun 30, 2023
VIRTU FINANCIAL LLC----53,501-100.00%-Jun 30, 2023
PNC FINANCIAL SERVICES GROUP, INC.----57,534-100.00%-Jun 30, 2023
MCADAM, LLC----62,169-100.00%-Jun 30, 2023
MORGAN STANLEY----88,216-100.00%-Jun 30, 2023
BANK OF NEW YORK MELLON CORP----88,715-100.00%-Jun 30, 2023
NORTHERN TRUST CORP----132,059-100.00%-Jun 30, 2023

As of Jun 30 2023, Hepion Pharmaceuticals's largest institutional buyer is ALLWORTH FINANCIAL LP. The company purchased -1.00 stocks of HEPA, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VANGUARD GROUP INC----3,310,180-100.00%-Jun 30, 2023
BLACKROCK INC.----1,602,772-100.00%-Jun 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----656,453-100.00%-Jun 30, 2023
STATE STREET CORP----313,500-100.00%-Jun 30, 2023
RENAISSANCE TECHNOLOGIES LLC----284,300-100.00%-Jun 30, 2023
ENVESTNET ASSET MANAGEMENT INC----156,909-100.00%-Jun 30, 2023
NORTHERN TRUST CORP----132,059-100.00%-Jun 30, 2023
BANK OF NEW YORK MELLON CORP----88,715-100.00%-Jun 30, 2023
MORGAN STANLEY----88,216-100.00%-Jun 30, 2023
MCADAM, LLC----62,169-100.00%-Jun 30, 2023
PNC FINANCIAL SERVICES GROUP, INC.----57,534-100.00%-Jun 30, 2023
VIRTU FINANCIAL LLC----53,501-100.00%-Jun 30, 2023
ADVISOR GROUP HOLDINGS, INC.----47,524-100.00%-Jun 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----31,535-100.00%-Jun 30, 2023
TWO SIGMA ADVISERS, LP----25,900-100.00%-Jun 30, 2023
CETERA INVESTMENT ADVISERS----19,746-100.00%-Jun 30, 2023
UBS GROUP AG----14,070-100.00%-Jun 30, 2023
AMUSSEN HUNSAKER ASSOCIATES LLC----13,306-100.00%-Jun 30, 2023
GROUP ONE TRADING, L.P.----13,128-100.00%-Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----10,564-100.00%-Jun 30, 2023

As of Jun 30 2023, Hepion Pharmaceuticals's biggest institutional seller is VANGUARD GROUP INC. The company sold -3.31M shares of HEPA, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VANGUARD GROUP INC----3,310,180-100.00%-Jun 30, 2023
BLACKROCK INC.----1,602,772-100.00%-Jun 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----656,453-100.00%-Jun 30, 2023
STATE STREET CORP----313,500-100.00%-Jun 30, 2023
RENAISSANCE TECHNOLOGIES LLC----284,300-100.00%-Jun 30, 2023
ENVESTNET ASSET MANAGEMENT INC----156,909-100.00%-Jun 30, 2023
NORTHERN TRUST CORP----132,059-100.00%-Jun 30, 2023
BANK OF NEW YORK MELLON CORP----88,715-100.00%-Jun 30, 2023
MORGAN STANLEY----88,216-100.00%-Jun 30, 2023
MCADAM, LLC----62,169-100.00%-Jun 30, 2023
PNC FINANCIAL SERVICES GROUP, INC.----57,534-100.00%-Jun 30, 2023
VIRTU FINANCIAL LLC----53,501-100.00%-Jun 30, 2023
ADVISOR GROUP HOLDINGS, INC.----47,524-100.00%-Jun 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----31,535-100.00%-Jun 30, 2023
TWO SIGMA ADVISERS, LP----25,900-100.00%-Jun 30, 2023
CETERA INVESTMENT ADVISERS----19,746-100.00%-Jun 30, 2023
UBS GROUP AG----14,070-100.00%-Jun 30, 2023
AMUSSEN HUNSAKER ASSOCIATES LLC----13,306-100.00%-Jun 30, 2023
GROUP ONE TRADING, L.P.----13,128-100.00%-Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----10,564-100.00%-Jun 30, 2023
AMPLIUS WEALTH ADVISORS, LLC----10,000-100.00%-Jun 30, 2023
CITADEL ADVISORS LLC----1,648-100.00%-Jun 30, 2023
WELLS FARGO & COMPANY/MN----528-100.00%-Jun 30, 2023
SIGNATUREFD, LLC----2-100.00%-Jun 30, 2023
HARBOR INVESTMENT ADVISORY, LLC----1-100.00%-Jun 30, 2023
ALLWORTH FINANCIAL LP----1-100.00%-Jun 30, 2023

Hepion Pharmaceuticals's largest sold out institutional shareholder by shares sold is VANGUARD GROUP INC, sold -3.31M shares, valued at -, as of undefined.

Hepion Pharmaceuticals Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD VALLEY FORGE FUNDS0.12%59,700--Dec 31, 2023
VANGUARD INDEX FUNDS0.01%3,161,576--Dec 31, 2023
VANGUARD VALLEY FORGE FUNDS0.01%2,985--Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%611,890--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%62,061--Dec 31, 2023
FIDELITY COMMONWEALTH TRUST0.00%3,018--Feb 29, 2024
SCHWAB CAPITAL TRUST0.00%31,535--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%201,82143,74127.67%Dec 31, 2023
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%3,104--Dec 31, 2023
SCHWAB CAPITAL TRUST0.00%1,577--Feb 29, 2024
iSHARES TRUST0.00%218,454--Feb 29, 2024
EQ ADVISORS TRUST0.00%11,560--Dec 31, 2023
Dimensional ETF Trust0.00%2,409--Jan 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%688--Jan 31, 2024
iSHARES TRUST0.00%2,798--Feb 29, 2024

Hepion Pharmaceuticals's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 59.70K shares, compromising 0.12% of its total assets.

Hepion Pharmaceuticals Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 2327-
31 Dec, 222717.39%
30 Sep, 2223-11.54%
30 Jun, 2226-21.21%
31 Mar, 2233-13.16%
31 Dec, 21382.70%
30 Sep, 2137-19.57%
30 Jun, 214621.05%
31 Mar, 213835.71%
31 Dec, 2028133.33%
30 Sep, 2012140.00%
30 Jun, 205-16.67%
31 Mar, 206-45.45%
31 Dec, 1911175.00%
30 Sep, 194-

As of 31 Mar 23, 27 institutions are holding Hepion Pharmaceuticals's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 236,994,261-0.65%
31 Dec, 227,040,2990.88%
30 Sep, 226,979,223-4.42%
30 Jun, 227,302,061-2.60%
31 Mar, 227,496,957-3.87%
31 Dec, 217,798,7542.21%
30 Sep, 217,630,225-26.88%
30 Jun, 2110,435,28038.85%
31 Mar, 217,515,35738.98%
31 Dec, 205,407,6682042.97%
30 Sep, 20252,34478.91%
30 Jun, 20141,044-32.38%
31 Mar, 20208,57516.68%
31 Dec, 19178,75514.82%
30 Sep, 19155,684-

Hepion Pharmaceuticals (HEPA) has 6.99M shares outstanding as of 31 Mar 23, down -0.65% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 23183.50%0.54%
31 Dec, 22184.71%0.55%
30 Sep, 22183.11%0.50%
30 Jun, 22191.58%0.50%
31 Mar, 22196.69%0.47%
31 Dec, 21204.61%0.51%
30 Sep, 21200.19%0.35%
30 Jun, 21240.13%0.80%
31 Mar, 21172.94%1.12%
31 Dec, 20124.44%369.04%
30 Sep, 205.81%55.12%
30 Jun, 203.25%14.09%
31 Mar, 204.80%28.37%
31 Dec, 194.11%20.24%
30 Sep, 194.51%-

As of 31 Mar 23, Hepion Pharmaceuticals is held by 183.50% institutional shareholders, representing a 0.54% growth compared to 31 Dec 22.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 2312-20.00%
31 Dec, 221566.67%
30 Sep, 229-
30 Jun, 229-35.71%
31 Mar, 2214-26.32%
31 Dec, 211946.15%
30 Sep, 2113-43.48%
30 Jun, 2123-25.81%
31 Mar, 213129.17%
31 Dec, 2024140.00%
30 Sep, 2010400.00%
30 Jun, 202-50.00%
31 Mar, 204-55.56%
31 Dec, 199125.00%
30 Sep, 194-

12 institutional shareholders have increased their position in HEPA stock as of 31 Mar 23 compared to 15 in the previous quarter (a -20.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 235-37.50%
31 Dec, 22860.00%
30 Sep, 225-44.44%
30 Jun, 229-
31 Mar, 229-
31 Dec, 219-30.77%
30 Sep, 21138.33%
30 Jun, 2112300.00%
31 Mar, 21350.00%
31 Dec, 202-
30 Sep, 20--100.00%
30 Jun, 201-
31 Mar, 201-50.00%
31 Dec, 192-
30 Sep, 19--

5 institutional shareholders have reduced their position in HEPA stock as of 31 Mar 23 compared to 8 in the previous quarter (a -37.50% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 2327-6,994,261-0.65%183.50%0.54%12-20.00%5-37.50%
31 Dec, 222717.39%7,040,2990.88%184.71%0.55%1566.67%860.00%
30 Sep, 2223-11.54%6,979,223-4.42%183.11%0.50%9-5-44.44%
30 Jun, 2226-21.21%7,302,061-2.60%191.58%0.50%9-35.71%9-
31 Mar, 2233-13.16%7,496,957-3.87%196.69%0.47%14-26.32%9-
31 Dec, 21382.70%7,798,7542.21%204.61%0.51%1946.15%9-30.77%
30 Sep, 2137-19.57%7,630,225-26.88%200.19%0.35%13-43.48%138.33%
30 Jun, 214621.05%10,435,28038.85%240.13%0.80%23-25.81%12300.00%
31 Mar, 213835.71%7,515,35738.98%172.94%1.12%3129.17%350.00%
31 Dec, 2028133.33%5,407,6682042.97%124.44%369.04%24140.00%2-
30 Sep, 2012140.00%252,34478.91%5.81%55.12%10400.00%--100.00%
30 Jun, 205-16.67%141,044-32.38%3.25%14.09%2-50.00%1-
31 Mar, 206-45.45%208,57516.68%4.80%28.37%4-55.56%1-50.00%
31 Dec, 1911175.00%178,75514.82%4.11%20.24%9125.00%2-
30 Sep, 194-155,684-4.51%-4---

Hepion Pharmaceuticals Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Nov 28, 2023Wijngaard Peterdirector-P-PurchaseBuy2,500$3.05$7.63K9,501
Nov 28, 2023Wijngaard Peterdirector-P-PurchaseBuy2,500$3.09$7.72K7,001
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy1,000$5.64$5.64K4,501
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy861$5.37$4.62K3,501
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy139$5.45$757.552,640
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy1,000$5.82$5.82K2,501
Sep 19, 2023Foster Robert Tdirector, officer CEO and DirectorP-PurchaseBuy1,600$5.60$8.96K50,470
Sep 18, 2023Foster Robert Tdirector, officer CEO,CSO and DirectorP-PurchaseBuy1,600$5.40$8.64K48,870

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Nov 28, 2023Wijngaard Peterdirector-P-PurchaseBuy2,500$3.05$7.63K9,501
Nov 28, 2023Wijngaard Peterdirector-P-PurchaseBuy2,500$3.09$7.72K7,001
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy1,000$5.64$5.64K4,501
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy861$5.37$4.62K3,501
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy139$5.45$757.552,640
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy1,000$5.82$5.82K2,501
Sep 19, 2023Foster Robert Tdirector, officer CEO and DirectorP-PurchaseBuy1,600$5.60$8.96K50,470
Sep 18, 2023Foster Robert Tdirector, officer CEO,CSO and DirectorP-PurchaseBuy1,600$5.40$8.64K48,870

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jul 20, 2022Lbiati Kaouthardirector-Sell60,000$0.69$41.40K-
Jul 05, 2022Reddi Ananddirector-Sell60,000$0.69$41.40K-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 07, 2024Purcell Michael J.director-A-AwardBuy50,000--50,000
Mar 06, 2024Purcell Michael J.director Buy----
Feb 21, 2024Block Timothy M.director-A-AwardBuy85,000$2.56$217.60K99,562
Feb 21, 2024JACOB GARY Sdirector-A-AwardBuy85,000$2.56$217.60K102,120
Feb 21, 2024Lbiati Kaouthardirector-A-AwardBuy85,000$2.56$217.60K88,000
Feb 21, 2024BRANCACCIO JOHN Pdirector, officer ChairmanA-AwardBuy85,000$2.56$217.60K99,563
Nov 28, 2023Wijngaard Peterdirector-P-PurchaseBuy2,500$3.05$7.63K9,501
Nov 28, 2023Wijngaard Peterdirector-P-PurchaseBuy2,500$3.09$7.72K7,001
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy1,000$5.64$5.64K4,501
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy861$5.37$4.62K3,501
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy139$5.45$757.552,640
Sep 20, 2023Wijngaard Peterdirector-P-PurchaseBuy1,000$5.82$5.82K2,501
Sep 19, 2023Foster Robert Tdirector, officer CEO and DirectorP-PurchaseBuy1,600$5.60$8.96K50,470
Sep 18, 2023Foster Robert Tdirector, officer CEO,CSO and DirectorP-PurchaseBuy1,600$5.40$8.64K48,870
Jul 20, 2022Lbiati Kaouthardirector-Sell60,000$0.69$41.40K-
Jul 05, 2022Reddi Ananddirector-Sell60,000$0.69$41.40K-
May 20, 2021Lippa Arnolddirector-A-AwardBuy200,000$1.70$340.00K291,110
May 20, 2021Wijngaard Peterdirector-A-AwardBuy200,000$1.70$340.00K260,000
May 20, 2021JACOB GARY Sdirector-A-AwardBuy250,000$1.70$425.00K342,785
May 20, 2021Foster Robert Tdirector, officer CEO, CSO and DirectorA-AwardBuy1,900,000$1.70$3.23M2,501,879

The last insider sell of Hepion Pharmaceuticals's stock was made by Lbiati Kaouthar on Jul 20 2022, selling 60,000 shares at $0.69 per share (valued at $41.40K). The last insider buy of HEPA was made by Wijngaard Peter on Nov 28 2023, buying 2,500 shares at $3.05 per share (worth $7.63K).

Hepion Pharmaceuticals Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20245--
Q4 20232--
Q3 20236--
Q2 2022-2-
Q2 20218--
Q1 20213--
Q4 20205--
Q3 20208--
Q2 20208--
Q3 20197--
Q1 2019-1-
Q3 20188--
Q1 20183--
Q3 20175--
Q2 201721200.00%
Q1 20172--
Q4 20161250.00%
Q3 201663200.00%
Q2 201622100.00%
Q1 20161250.00%

5 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Hepion Pharmaceuticals's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2024---
Q4 20232--
Q3 20236--
Q2 2022---
Q2 2021---
Q1 20213--
Q4 20205--
Q3 2020---
Q2 2020---
Q3 2019---
Q1 2019---
Q3 20188--
Q1 2018---
Q3 2017---
Q2 20171--
Q1 2017---
Q4 2016---
Q3 2016---
Q2 2016---
Q1 20161--

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Hepion Pharmaceuticals's stocks.

Hepion Pharmaceuticals Peer Ownership


TickerCompany
ZURAZura Bio Limited
CWBRCohBar, Inc.
ELEVElevation Oncology, Inc.
OCEAOcean Biomedical, Inc.
EFTReFFECTOR Therapeutics, Inc.
AVROAVROBIO, Inc.
ENVBEnveric Biosciences, Inc.

HEPA Ownership FAQ


Hepion Pharmaceuticals is owned by institutional shareholders (183.50%), insiders (0.31%), and public (-83.81%). The largest institutional shareholder of Hepion Pharmaceuticals is WELLS FARGO & COMPANY/MN (0% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.12% of total shares).

Hepion Pharmaceuticals's major institutional shareholders are WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, STATE STREET CORP, VANGUARD GROUP INC, and PNC FINANCIAL SERVICES GROUP, INC.. The top five shareholders own together 0% of the company's share outstanding.

As of Mar 2023, there are 27 institutional shareholders of Hepion Pharmaceuticals.

WELLS FARGO & COMPANY/MN owns 0 shares of Hepion Pharmaceuticals, representing 0% of the company's total shares outstanding, valued at $0 (as of Jun 2023).

As of Jun 2023, NORTHERN TRUST CORP holds 0 shares of Hepion Pharmaceuticals (HEPA), compromising 0% of the company, valued at $0.

STATE STREET CORP is the third largest holder of Hepion Pharmaceuticals. The company owns 0 of the company's shares outstanding (worth $0).